ArticleMolecular & cellular proteomics : MCP2018
Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies.
Article in Molecular & cellular proteomics : MCP, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Multiplexed in situ protein imaging using DNA-barcoded antibodies with extended hybridization chain reactions.Nucleic acids research · 2024Article
- CD34 as a potential prognostic indicator for camrelizumab response in advanced non-small-cell lung cancer: insights from digital spatial profiling.Therapeutic advances in medical oncology · 2024Article
- CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer.Future oncology (London, England) · 2024Article
- Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer.Nature communications · 2023Article
- An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer.Cell reports. Medicine · 2022Article
- Candidate biomarker assessment for pharmacological response.Translational oncology · 2020Article
- Multiplex digital spatial profiling of proteins and RNA in fixed tissue.Nature biotechnology · 2020Article
- Virtual Issue: Technological Innovations.Molecular & cellular proteomics : MCP · 2020Article
- Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma.British journal of cancer · 2020Article
- Proteomics advances for precision therapy in ovarian cancer.Expert review of proteomics · 2019Review
- A user's perspective on GeoMxImmuno-oncology technology · 2019Review
- Tissue Imaging by Mass Spectrometry: A Practical Guide for the Medicinal Chemist.ACS medicinal chemistry letters · 2019Article
- Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance.Advances in experimental medicine and biology · 2019Review
- Credentialing Individual Samples for Proteogenomic Analysis.Molecular & cellular proteomics : MCP · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Molecular analysis of tumors forms the basis for personalized cancer medicine and increasingly guides patient selection for targeted therapy. Future opportunities for personalized medicine are highlighted by the measurement of protein expression levels via immunohistochemistry, protein arrays, and other approaches; however, sample type, sample quantity, batch effects, and "time to result" are limiting factors for clinical application. Here, we present a development pipeline for a novel multiplexed DNA-labeled antibody platform which digitally quantifies protein expression from lysate samples. We implemented a rigorous validation process for each antibody and show that the platform is amenable to multiple protocols covering nitrocellulose and plate-based methods. Results are highly reproducible across technical and biological replicates, and there are no observed "batch effects" which are common for most multiplex molecular assays. Tests from basal and perturbed cancer cell lines indicate that this platform is comparable to orthogonal proteomic assays such as Reverse-Phase Protein Array, and applicable to measuring the pharmacodynamic effects of clinically-relevant cancer therapeutics. Furthermore, we demonstrate the potential clinical utility of the platform with protein profiling from breast cancer patient samples to identify molecular subtypes. Together, these findings highlight the potential of this platform for enhancing our understanding of cancer biology in a clinical translation setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.